China's National Medical Products Administration on Wednesday approved a domestic COVID-19 therapy for emergency use.
The approved BRII-196/BRII-198 is a COVID-19 neutralizing monoclonal antibody combination therapy.
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3